Aaron Osborne, MD

Dr. Aaron Osborne has 15 years of experience in the biopharmaceutical industry together which have been mainly focused on developing therapies for retinal disease. He most recently served as Chief Medical Officer at Adverum Biotechnologies, a gene therapy company. Prior to that, Dr. Osborne was principal medical director, at Genentech Inc, where he was responsible for leading the faricimab clinical development program in wet age-related macular degeneration and diabetic macular edema. Previously, Dr. Osborne was the pharmaceuticals franchise head, Global Medical Affairs for Alcon Research Ltd. Prior to Alcon, Dr. Osborne served as global medical affairs head, Ophthalmics, at Novartis Pharma AG, and as global brand medical director, Lucentis, at Novartis Pharma AG. Dr. Osborne trained in ophthalmology at Nottingham University, becoming a member of the Royal College of Ophthalmologists in 2004. He earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree at University College London.